Stockscreener 앱 받기
12.79
3.18%
-0.42
전일 마감가:
$13.21
열려 있는:
$13.53
하루 거래량:
665.96K
Relative Volume:
0.67
시가총액:
$913.34M
수익:
$133.62M
순이익/손실:
$-177.37M
주가수익비율:
-4.4256
EPS:
-2.89
순현금흐름:
$23.50M
1주 성능:
-7.92%
1개월 성능:
-22.72%
6개월 성능:
+44.85%
1년 성능:
-36.15%
1일 변동 폭
$12.76
$13.65
1주일 범위
$12.76
$14.65
52주 변동 폭
$6.92
$21.00
Xencor Inc Stock (XNCR) Company Profile
명칭
Xencor Inc
전화
626-305-5900
주소
465 N. HALSTEAD ST., PASADENA, CA
XNCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
12.79 | 943.33M | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-10-29 | 업그레이드 | Barclays | Underweight → Overweight |
| 2025-09-17 | 재개 | Barclays | Underweight |
| 2025-09-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-04-21 | 개시 | William Blair | Outperform |
| 2024-12-12 | 개시 | Wells Fargo | Overweight |
| 2024-12-02 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 재확인 | BTIG Research | Buy |
| 2024-02-28 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 개시 | BofA Securities | Buy |
| 2022-12-06 | 개시 | Cowen | Outperform |
| 2022-10-13 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 개시 | JP Morgan | Overweight |
| 2022-07-06 | 재개 | Canaccord Genuity | Buy |
| 2022-02-11 | 개시 | BMO Capital Markets | Outperform |
| 2022-01-21 | 개시 | SMBC Nikko | Outperform |
| 2021-12-15 | 개시 | H.C. Wainwright | Buy |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2021-02-24 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 개시 | Barclays | Underweight |
| 2020-02-25 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-01-30 | 개시 | RBC Capital Mkts | Outperform |
| 2019-11-20 | 재개 | Guggenheim | Neutral |
| 2019-08-07 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-08-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 개시 | Mizuho | Buy |
| 2019-04-12 | 개시 | Guggenheim | Buy |
| 2019-03-27 | 개시 | Berenberg | Buy |
| 2019-03-15 | 개시 | Raymond James | Outperform |
| 2018-09-10 | 재개 | BTIG Research | Buy |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2017-03-02 | 개시 | Instinet | Neutral |
| 2017-03-02 | 재확인 | Wedbush | Outperform |
| 2016-10-04 | 개시 | Piper Jaffray | Overweight |
| 2015-12-22 | 개시 | Canaccord Genuity | Buy |
| 2015-08-05 | 재확인 | MLV & Co | Buy |
| 2015-02-12 | 재확인 | Oppenheimer | Outperform |
| 2015-01-28 | 재확인 | MLV & Co | Buy |
| 2014-07-11 | 개시 | Oppenheimer | Outperform |
모두보기
Xencor Inc 주식(XNCR)의 최신 뉴스
Navigating the Valuation Gap in Xencor Shares - AD HOC NEWS
Xencor (NASDAQ:XNCR) Shares Down 7.1%Here's Why - MarketBeat
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving Average – Time to Sell? - Defense World
[Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Merger Talk: What hedge fund activity signals for Xencor Inc stockJuly 2025 Action & Accurate Intraday Trade Tips - Bộ Nội Vụ
Xencor (NASDAQ:XNCR) Shares Pass Below 50-Day Moving AverageTime to Sell? - MarketBeat
Performance Recap: Can Xencor Inc stock outperform in a bear marketMarket Risk Report & Safe Capital Growth Plans - baoquankhu1.vn
Weekly Earnings: Is Xencor Inc a top pick in the sector2025 Trading Recap & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
ImmunityBio, Xencor Drugs Win E.U. Nods - Los Angeles Business Journal
How supply shortages influence Xencor Inc. (XE9) stockJuly 2025 Summary & High Accuracy Investment Entry Signals - Улправда
Xencor, Inc.Common Stock (NQ: XNCR - FinancialContent
Xencor outlines 2026 pipeline plans for cancer and autoimmune drugs By Investing.com - Investing.com Nigeria
IPO Launch: Will Xencor Inc stock reach Wall Street targetsWeekly Trade Summary & Daily Momentum Trading Reports - Bộ Nội Vụ
Xencor, Inc. (XNCR) Stock Analysis: Biotech Innovator With Over 100% Potential Upside - DirectorsTalk Interviews
Will Xencor Inc. stock benefit from upcoming earnings reports2025 Price Targets & Weekly Return Optimization Alerts - Улправда
How Xencor Inc. stock reacts to Fed rate cuts2025 Top Decliners & High Accuracy Investment Entry Signals - Улправда
Will Xencor Inc. stock reach Wall Street targetsQuarterly Investment Review & Community Consensus Trade Alerts - Улправда
Is Xencor Inc. stock in correction or buying zoneQuarterly Profit Summary & AI Based Trade Execution Alerts - ulpravda.ru
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones - BioSpace
Xencor expects to have sufficient cash resources to fund research and development programs and operations through 2028 - marketscreener.com
Xencor Expects To Have Sufficient Cash Resources To Fund Research And Development Programs And Operations Through 2028 - TradingView — Track All Markets
Xencor outlines 2026 pipeline plans for cancer and autoimmune drugs - Investing.com
Bank of America Securities Sticks to Their Hold Rating for Xencor (XNCR) - The Globe and Mail
Star TribuneXencor, Inc.Common Stock (Nasdaq:XNCR) Stock Quote - FinancialContent
Xencor (NASDAQ:XNCR) Trading Down 7.1%Time to Sell? - MarketBeat
Incyte marks trial win for Xencor lymphoma drug (INCY:NASDAQ) - Seeking Alpha
Trading the Move, Not the Narrative: (XNCR) Edition - Stock Traders Daily
The Truth About Xencor Inc: Is This Quiet Biotech About To Explode? - AD HOC NEWS
Xencor: Fortress Balance Sheet Bodes Well For XmAb819 And XmAb942 (NASDAQ:XNCR) - Seeking Alpha
Calculating The Fair Value Of Xencor, Inc. (NASDAQ:XNCR) - Yahoo Finance
Xencor issued US patent for Xtend FC domain - MSN
Xencor (NASDAQ:XNCR) VP John Desjarlais Sells 73,367 Shares - MarketBeat
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 114,377 Shares of Stock - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Xencor SVP Desjarlais sells $1.15 million in shares By Investing.com - Investing.com Nigeria
Responsive Playbooks and the XNCR Inflection - Stock Traders Daily
Xencor SVP Desjarlais sells $1.15 million in shares - Investing.com
With Xencor Stock Sliding, Have You Assessed The Risk? - Trefis
What drives Xencor Inc stock priceMarket Liquidity Analysis & Learn the Secrets of Pro Traders - earlytimes.in
Will Xencor Inc. (XE9) stock remain on Wall Street radar2025 Biggest Moves & Entry Point Strategy Guides - Улправда
Why Xencor Inc. stock attracts global investors2025 Institutional Moves & Low Risk High Reward Ideas - Улправда
VP Desjarlais Files To Sell 73,367 Of Xencor Inc [XNCR] - TradingView — Track All Markets
Can Xencor Inc. stock sustain revenue growth2025 Market Overview & Fast Gain Stock Trading Tips - Улправда
Growth Report: Is Xencor Inc. stock ready for breakoutPortfolio Return Report & Free Safe Entry Trade Signal Reports - Улправда
Can Xencor Inc. stock resist market sell offsJuly 2025 News Drivers & AI Powered Buy/Sell Recommendations - Улправда
Xencor Faces Structural Headwinds As Long-Term Momentum Fades - Benzinga
Xencor Inc (XNCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Xencor Inc 주식 (XNCR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Desjarlais John R | SR. VICE PRESIDENT & CSO |
Dec 22 '25 |
Option Exercise |
12.51 |
6,311 |
78,951 |
242,885 |
| Desjarlais John R | SR. VICE PRESIDENT & CSO |
Dec 19 '25 |
Sale |
15.72 |
73,367 |
1,153,329 |
236,574 |
| Dahiyat Bassil I | PRESIDENT & CEO |
Dec 19 '25 |
Option Exercise |
12.51 |
114,377 |
1,430,856 |
581,012 |
| Dahiyat Bassil I | PRESIDENT & CEO |
Dec 22 '25 |
Option Exercise |
12.51 |
10,624 |
132,906 |
477,259 |
| Dahiyat Bassil I | PRESIDENT & CEO |
Dec 19 '25 |
Sale |
15.71 |
114,377 |
1,796,863 |
466,635 |
4.73%
0.92%
자본화:
|
볼륨(24시간):